EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFV600E/K-mutant metastatic melanoma

Yuan J Pétermann, Alicja Puszkiel, Abbas Khani, Nora Kramkimel, Elisa Funck-Brentano, Benédicte Oules, Sarah Bouchereau, Michel Vidal, Xavier Decleves, Chantal Csajka, Benoit Blanchet, Monia Guidi

Cancer Chemotherapy and Pharmacology · 2026

DOI: 10.1007/s00280-026-04876-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Yuan J Pétermann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 17, CH…. Hauptthemen laut MEDLINE: Carbamates, Benzimidazoles, Melanoma, Proto-Oncogene Proteins B-raf. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Encorafenib and binimetinib pharmacokinetic (PK) studies in real-world cancer patients remain scarce. We aimed to characterize their population pharmacokinetics (popPK) in routine clinical care and compare real-life exposure metrics with clinical trials data.

Methods

We conducted population pharmacokinetic (popPK) analyses in real-world patients with BRAF V600E/K -mutant metastatic melanoma to characterize interindividual variability (IIV) and identify significant covariates in MonolixSuite™. Final model-based Bayesian individual PK metrics (i.e., trough concentration, C min , maximal concentration, C max , unbound average concentration, C average , and area under the curve, AUC τ ) were compared with data from clinical trials and potency-anchored metrics (reported half-maximal inhibitory concentration, IC 50 ).

Results

Data from 66 encorafenib and 69 binimetinib patients (310 and 311 samples) were analyzed. For both drugs, a two-compartment model with first-order absorption and linear elimination best described the data. None of the studied covariates were significantly associated with model parameters. Model-predicted PK metrics (geometric mean and CV(%)) for encorafenib and binimetinib at 450 mg QD and 45 mg BID were: C min 19 ng/mL (73%) and 55 ng/mL (56%), C max 3378 ng/mL (30%) and 367 ng/mL (24%), and half-lives 12.5 h (95%) and 7.3 h (67%), respectively. Encorafenib AUC 24h was 15,785 ng·h/mL (17%) and binimetinib AUC 12h was 2003 ng·h/mL (22%). Monte Carlo simulation showed that reducing encorafenib from 450 mg to 300 mg once daily lowered unbound C average by 33% while maintaining substantial coverage relative to IC 50 .

Conclusion

Overall, these metrics are comparable to those reported in clinical trial data. This population PK model could be useful to explore the exposure-response relationship in future PK/PD studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbamatesBenzimidazolesMelanomaProto-Oncogene Proteins B-rafSulfonamidesModels, BiologicalHumansMaleFemaleMiddle AgedAgedAdultMutationArea Under CurveAged, 80 and over

Stichwörter der Autor:innen

BinimetinibEncorafenibOncologyPopulation PharmacokineticReal-world dataTherapeutic drug monitoring

Substanzen

encorafenibbinimetinibCarbamatesBenzimidazolesProto-Oncogene Proteins B-rafSulfonamidesBRAF protein, human

Autor:innen und Institutionen

  • Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 17, CH-1011 , Lausanne, Switzerland.
  • Biologie du Médicament - Toxicologie, Cochin University Hospital, AP-HP, CARPEM, Paris, France.
  • Université Paris Cité, INSERM, Optimisation thérapeutique en neuropharmacologie OTEN U1144, Paris, 75006, France.
  • Neurotechnology Group, Institute of Neuroinformatics, ETH Zurich, Zurich, Switzerland.
  • Dermatology Department, Cochin University Hospital, AP-HP, Paris, France.
  • Department of General and Oncologic Dermatology, Ambroise Paré hospital, APHP, EA 4340 "Biomarkers in cancerology and hemato-oncology", UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France.

Zitieren

APA

Pétermann, Y. J., Puszkiel, A., Khani, A., Kramkimel, N., Funck-Brentano, E., Oules, B., Bouchereau, S., Vidal, M., Decleves, X., Csajka, C., Blanchet, B., & Guidi, M. (2026). Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFV600E/K-mutant metastatic melanoma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04876-y

Vancouver

Pétermann YJ, Puszkiel A, Khani A, Kramkimel N, Funck-Brentano E, Oules B, et al. Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFV600E/K-mutant metastatic melanoma. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04876-y

BibTeX
@article{Ptermann2026,
  author = {Pétermann, Yuan J and Puszkiel, Alicja and Khani, Abbas and Kramkimel, Nora and Funck-Brentano, Elisa and Oules, Benédicte and Bouchereau, Sarah and Vidal, Michel and Decleves, Xavier and Csajka, Chantal and Blanchet, Benoit and Guidi, Monia},
  title = {Population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAFV600E/K-mutant metastatic melanoma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  doi = {10.1007/s00280-026-04876-y}
}
Kostenlos starten →